Company: NDRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001654954-25-009643
Chunk: 5

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
  (2,229,153)Balance as of June 30,2024  17,488  $-   -  $-   41,394  $3  $105,928,916  $27  $(96,935,005) $8,993,941 

Three Months Ended June 30,2025 Series A Convertible  Series B Convertible      Additional      Total   Preferred Stock  Preferred Stock  Common stock  Paid in  Stock  Accumulated  Stockholders'   Shares  Amount  Shares  Amount  Shares  Amount  Capital  Payable  Deficit  Equity Balance as of March 31, 2025  17,488  $-   -  $-   562,213  $55  $106,227,259   -  $(104,474,429) $1,752,885 Preferred stock conversion to common stock  -   -   -   -   -   -   -   -   -   - Common stock issued for cash  -   -   -   -   190,177   19   857,396   -   -   857,415 Fair value of vested stock options  -   -   -   -   -   -   49,233   -   -   49,233 Fair value of vested restricted stock units  -   -   -   -   -   -   39,530   -   -   39,530 Net loss  -   -   -   -   -   -   -   -   (1,225,912)  (1,225,912)Balance as of June 30,2025  17,488  $-   -  $-   752,390  $74  $107,173,418  $-  $(105,700,341) $1,473,151 

The accompanying notes are an integral part of these unaudited condensed consolidated financial